13Dec

[2018 Round-up] Movement disorders in 2018: tackling this evil at the roots

In 2018, several initiatives that have aimed to slow progression or prevent development of movement disorders have provided encouraging results. In mouse models of Parkinson's disease, drugs that activate glucagon-like peptide 1 (GLP-1) receptors have been shown to target neuroinflammation, reduce microglial activation following exposure to aggregated α-synuclein, and prevent microglial-mediated conversion of astrocytes to a neurotoxic phenotype.1 Mild improvements of motor scores in patients with Parkinson's disease who were treated with the GLP-1 receptor agonist exenatide compared with placebo2 need to be confirmed in other studies (NCT02953665 for liraglutide, NCT03659682 for semaglutide).

Ander nieuws

20May

[Review] CSF and blood biomarkers for Parkinson’s disease

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urg...

naar nieuwsitem

20May

[Comment] A new step towards targeting tau

Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkins...

naar nieuwsitem

22Apr

Parkinson’s disease patient: ‘I can walk… it’s really helped me’

Parkinson's disease patient Gail Jardine can walk more freely after having a spinal implant fit...

naar nieuwsitem